ML
Matthew L. Posard sold $568K of HALO stock
Matthew L. Posard, Dir of Halozyme Therapeutics, Inc. (HALO), sold 5,230 shares of HALO stock worth $568K, per an SEC Form 4 filed Oct 2, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Oct 1, 2026, 1 day before it was made public.
HALO has moved -6.2% since the trade date, from $106.94 to $100.27 (Nov 13, 2026 close).
- Traded
- Oct 1, 2026
- Disclosed
- Oct 2, 2026
- Filing delay
- 1 day
- Price since
- -6.2%
- Role
- Dir
- Source
- SEC Form 4